Evidence map›Paper›PMID 29055972›Full record

Observational studyESC heart failure2018

Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure.

Yoshiaki Kubota, Wan Ting Tay, Kuniya Asai, Koji Murai, Ikutaro Nakajima, Nobuhisa Hagiwara, Takanori Ikeda, Takashi Kurita, Tiew-Hwa Katherine Teng, Inder Anand and 3 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yoshiaki KubotaDepartment of Cardiovascular Medicine, Nippon Medical School, Bunkyō, Tokyo, Japan.
Wan Ting TayNational Heart Centre Singapore, Singapore, Singapore.
Kuniya AsaiDepartment of Cardiovascular Medicine, Nippon Medical School, Bunkyō, Tokyo, Japan.
Koji MuraiDepartment of Cardiovascular Medicine, Nippon Medical School, Bunkyō, Tokyo, Japan.
Ikutaro NakajimaDivision of Cardiology, Department of Internal Medicine, National Cerebral and Cardiovascular Center Hospital, Suita, Osaka, Japan.
Nobuhisa HagiwaraDepartment of Cardiology, School of Medicine, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.
Takanori IkedaDivision of Cardiovascular Medicine, Department of Internal Medicine, Toho University Omori Hospital, Ōta, Tokyo, Japan.
Takashi KuritaDivision of Cardiology, Department of Internal Medicine, Kinki University School of Medicine, Higashiōsaka, Osaka, Japan.
Tiew-Hwa Katherine TengNational Heart Centre Singapore, Singapore, Singapore.
Inder AnandVA Medical Center, University of Minnesota, Minneapolis, MN, USA.
Carolyn S P LamNational Heart Centre Singapore, Singapore, Singapore.
Wataru ShimizuDepartment of Cardiovascular Medicine, Nippon Medical School, Bunkyō, Tokyo, Japan.
ASIA-HF Study investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsChronic obstructive pulmonary disease (COPD) and heart failure (HF) are increasingly frequent in Asia and commonly coexist in patients. However, the prevalence of COPD among Asian patients with HF and its impact on HF treatment are unclear. METHODS AND

resultsWe compared clinical characteristics and treatment approaches between patients with or without a history of COPD, before and after 1:2 propensity matching (for age, sex, geographical region, income level, and ethnic group) in 5232 prospectively recruited patients with HF and reduced ejection fraction (HFrEF, <40%) from 11 Asian regions (Northeast Asia: South Korea, Japan, Taiwan, Hong Kong, and China; South Asia: India; Southeast Asia: Thailand, Malaysia, Philippines, Indonesia, and Singapore). Among the 5232 patients with HFrEF, a history of COPD was present in 8.3% (n = 434), with significant variation in geography (11.0% in Northeast Asia vs. 4.7% in South Asia), regional income level (9.7% in high income vs. 5.8% in low income), and ethnicity (17.0% in Filipinos vs. 5.2% in Indians) (all P < 0.05). Use of mineralocorticoid receptor antagonists and diuretics was similar between groups, while usage of all β-blockers was lower in the COPD group than in the non-COPD group in the overall (66.3% vs. 79.9%) and propensity-matched cohorts (66.3% vs. 81.7%) (all P < 0.05). A striking exception was the Japanese cohort in which β-blocker use was high in COPD and non-COPD patients (95.2% vs. 91.2%).

conclusionsThe prevalence of COPD in HFrEF varied across Asia and was related to underuse of β-blockers, except in Japan.

Indexed as

Adrenergic beta-AntagonistsAsia, SoutheasternComorbidityFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedPrognosisProspective StudiesPulmonary Disease, Chronic ObstructiveStroke VolumeAdrenergic beta-AntagonistsChronic obstructive pulmonary diseaseHeart failureβ-Blocker

Identifiers

PMID29055972
PMCPMC5880660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.